Bibliografie tematiche / Gemfibrozilo

Indice

  1. Articoli di riviste
  2. Tesi
  3. Libri
  4. Capitoli di libri
  5. Atti di convegni

Letteratura scientifica selezionata sul tema "Gemfibrozilo"

Autore: Grafiati
Pubblicato: 4 giugno 2021
Ultima modifica: 6 febbraio 2022

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Gemfibrozilo".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Articoli di riviste sul tema "Gemfibrozilo"

1

Maguiña, Elbis, Fernando Nuevo V. e Jesús Rumiche B. "Análisis costo-efectividad del uso de estatinas frente a gemfibrozilo en pacientes de consultorios externos del Centro Médico Naval: "Cirujano Mayor Santiago Tavara"". Ciencia e Investigación 9, n. 1 (19 giugno 2006): 33–40. http://dx.doi.org/10.15381/ci.v9i1.5090.

Testo completo
Abstract (sommario):
El objetivo de la investigación fue determinar y comparar el costo-efectividad de Atorvastatina 20 mG y Pravastatina 20m mG trente a Gemfibrozilo 600mG, en el tratamiento de hiperlipidemia, e identificar los factores de riesgo. Fue un estudio transversal, descriptivo y retrospectivo, realizado en el Centro Médico Naval, en el período de enero de 2002 a julio de 2005. Se revisaron historias clínicas de 64 pacientes hiperlipidémicos, entre 40 y 64 años, que acuden a los consultorios externos de Cardiología, Endocrinología, Geriatría y Medicina Interna a quienes se les prescribió: Estatinas 20 mg/ día o Gemfibrozilo 600 mg/ día. La efectividad se determinó según el National Cholesterol Education Program (NCEP2001). Se aplicó una encuesta para conocer problemas de cumplimiento de terapia. Según el análisis costo-efectividad (reducción del nivel sérico de LDL-c), las Estatinas reportan una relación costo-efectiva de 13,76 nuevos soles por porcentaje de reducción; y el Gemfibrozilo, no resultó efectivo. Por reducción de nivel de triglicéridos, el Gemfibrozilo presentó una relación cost-efectiva de 1,74 nuevos soles por porcentaje de reducción y las Estatinas no fueron efectivas. Según logro de objetivos terapéuticos, el Gemfibrozilo presentó una relación costo-efectiva menor (361,2 nuevos soles por paciente), debido a su menor costo.
Gli stili APA, Harvard, Vancouver, ISO e altri
2

García Llopis, Paula, Alejandra González D’huicque e Vicente Palop Larrea. "Edema facial por gemfibrozilo". Medicina Clínica 135, n. 8 (settembre 2010): 384. http://dx.doi.org/10.1016/j.medcli.2009.06.040.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Acuña Elvira, Nerea. "Consulta farmacéutica: intoxicación por gemfibrozilo". Farmacéuticos Comunitarios 9, n. 2 (30 luglio 2017): 49–51. http://dx.doi.org/10.5672/fc.2173-9218.(2017/vol9).002.06.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Tormo Molina, J., I. Gázquez Pérez e A. Matas Hoces. "Cerivastatina y gemfibrozilo: una combinación peligrosa*". Atención Primaria 28, n. 6 (2001): 438–39. http://dx.doi.org/10.1016/s0212-6567(01)70410-6.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

de Arriba Méndez, José-Javier, Elena Gómez Merino, José Antonio Sáez Barcelona e Lourdes Sáez Méndez. "Rabdomiólisis grave asociada a cerivastatina y gemfibrozilo". Medicina Clínica 117, n. 7 (gennaio 2001): 278–79. http://dx.doi.org/10.1016/s0025-7753(01)72086-6.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Bosch Rovira, T., J. A. Llompart Pou e J. Forteza-Rey. "Rabdomiólisis asociada al tratamiento combinado con cerivastatina y gemfibrozilo". Revista Clínica Española 201, n. 12 (gennaio 2001): 731–32. http://dx.doi.org/10.1016/s0014-2565(01)70966-6.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Vascónez Espinosa, F., N. Gómez Rodríguez, A. Martín Joven e F. J. Posada García. "Rabdomiólisis complicada con insuficiencia renal aguda en un paciente tratado con gemfibrozilo y cerivastatina". Revista Clínica Española 201, n. 4 (gennaio 2001): 228–29. http://dx.doi.org/10.1016/s0014-2565(01)70806-5.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Alean Flórez, Joel, Daniela Márquez Méndez, Saudith María Burgos Núñez, Germán Enamorado-Montes e José Marrugo Negrete. "Productos farmacéuticos y de cuidado personal presentes en aguas superficiales, de consumo humano y residuales en el departamento de Córdoba, Colombia". Revista de Investigación Agraria y Ambiental 12, n. 2 (2 giugno 2021): 179–97. http://dx.doi.org/10.22490/21456453.4231.

Testo completo
Abstract (sommario):
Contextualización: gracias al avance de técnicas analíticas sensibles desarrolladas en las últimas décadas, se ha podido identificar y cuantificar la presencia de diversos contaminantes en el medio acuático, dentro de este grupo se encuentran los contaminantes emergentes (CE) conformados por productos de cuidado e higiene personal, antibióticos, hormonas, plastificantes, fármacos y otros que son vertidos a las fuentes de agua alterando el equilibrio de estos ecosistemas. Vacío de investigación: diversas investigaciones muestran que los contaminantes emergentes pueden comprometer la vida acuática y la salud humana. A la fecha en la ciudad de montería y en el departamento de Córdoba no se encuentran reportados ningún estudio que permita evidenciar la presencia de contaminantes emergentes en agua superficial, de consumo humano y residual. Propósito del estudio: el presente estudio, tuvo como objetivo evaluar la presencia de cinco contaminantes emergentes comunes: naproxeno, ibuprofeno, gemfibrozilo, cafeína y triclosán en muestras de agua de consumo humano, residual y superficial colectadas al norte del país, representando así uno de los primeros estudios en reportar la presencia de estos compuestos en fuentes hídricas en esta región. Metodología: se empleó extracción en fase sólida (SPE) para el análisis de las muestras de agua, la detección y cuantificación se realizó por cromatografía líquida de alta eficacia con detector de arreglo de diodo y fluorescencia molecular (HPLC-DAD-FLD). Resultados y conclusiones: el ibuprofeno fue el compuesto que se encontró con mayor frecuencia en las muestras de agua, caso contrario al triclosán, que fue el menos detectado (2.25 µg/L); se halló cafeína en un máximo de 43.38 µg/L mientras que las concentraciones de naproxeno e ibuprofeno estuvieron entre 0.047 y 10.21 µg/L, resaltando la presencia de ibuprofeno y gemfibrozilo en agua de consumo humano. Estos resultados manifiestan la presión antropogénica ejercida sobre los compartimientos acuáticos, convirtiéndose en un problema ambiental que compromete la dinámica y servicios ecosistémicos. Se encontró que las plantas de abastecimiento de agua no tienen en cuenta la presencia de estos compuestos en sus sistemas de potabilización, lo cual podría constituirse un problema de salud pública en un futuro.
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Jiménez-Bambague, Eliana M., Carlos A. Madera-Parra e Enrique J. Peña-Salamanca. "Eliminación de compuestos farmacéuticos presentes en el agua residual doméstica mediante un tratamiento primario avanzado". INGENIERÍA Y COMPETITIVIDAD 22, n. 1 (29 gennaio 2020): 10. http://dx.doi.org/10.25100/iyc.v22i1.8794.

Testo completo
Abstract (sommario):
Se evaluó la presencia de compuestos farmacéuticos de los grupos terapéuticos antiepilépticos, agentes hipolipemiantes, analgésicos antiinflamatorios y tranquilizantes en tres jornadas de muestreo, además se estimó la eficiencia de eliminación mediante un tratamiento primario avanzado (TPA) con procesos de coagulación, floculación y sedimentación en la planta de tratamiento de agua residual de la ciudad de Cali (Colombia). De los compuestos medidos, 10 estuvieron por encima del límite de detección de la técnica analítica usada: carbamazepina, 10,11-Dihidro-10,11-dihidroxicarbamazepina, gabapentina, ácido fenofíbrico, gemfibrozilo, diclofenaco, ibuprofeno, ketoprofeno, naproxeno y paracetamol, en concentraciones que oscilaron entre 0.15 y 10 µgL-1 en el afluente. Después del tratamiento, la mayoría de compuestos tuvieron eficiencias de eliminación inferiores al 30%, siendo el paracetamol y naproxeno los que obtuvieron los mejores porcentajes de 98.1 y 57.1%, respectivamente. Estas eficiencias de eliminación se relacionaron no solo al proceso de coagulación floculación, el cual es favorable para compuestos lipofílicos, sino también a la biodegradación por la acción de las bacterias presentes en la matriz de agua residual.
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Martín-Navarro, Juan Antonio, Vladimir Petkov-Stoyanov, María José Gutiérrez-Sánchez e Luis Pedraza-Cezón. "Fracaso renal agudo por nefritis intersticial aguda con síndrome de Fanconi en relación con metamizol y gemfibrozilo". Nefrología 36, n. 3 (maggio 2016): 321–23. http://dx.doi.org/10.1016/j.nefro.2015.06.022.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
Più fonti

Tesi sul tema "Gemfibrozilo"

1

Breña, Figueroa Mirtha Rocío. "Diseño y desarrollo de una formulación para Gemfibrozilo 600 mg. tableta recubierta". Bachelor's thesis, Universidad Nacional Mayor de San Marcos, 2005. https://hdl.handle.net/20.500.12672/2603.

Testo completo
Abstract (sommario):
En el presente trabajo se han evaluado tres formulaciones para Gemfibrozilo 600 mg tableta recubierta, una realizada por compresión directa y dos por granulación húmeda, de las cuales se ha seleccionado a la formulación que cumple los parámetros establecidos para el dosaje, disolución y los factores de deferencia (F1) y similitud (F2), estos factores fueron determinados a través de la comparación por perfil de disolución con respecto al producto innovador. Se realizó el estudio de estabilidad acelerada (40ºC ± 2 ºC / 75% de humedad relativa ± 5%.), estabilidad a largo plazo (25 ºC ± 2 ºC / 60% ± 5% de humedad relativa) y estabilidad intermedia (32 ºC C ± 2 ºC / 65% de humedad relativa ± 5%. ) de la formulación que cumplió las especificaciones anteriormente mencionados, en dos tipos de empaque primario (Blister de Aluminio y PVC 250 um y 300 um) y al producto de referencia, los periodos de tiempo de los análisis fueron al iniciar el estudio de estabilidad (tiempo inicial), a los 3 meses, 6 meses y en el caso de la estabilidad a condiciones ambientales hasta los 12 meses. La metodología utilizada para el análisis fisicoquímico se basó en la Farmacopea de los Estados Unidos (USP 26 – NF 21) y la Farmacopea Británica (BP 2003) y el análisis microbiológico se basó en la European Pharmacopoeia 4ta Ed. 2002, los análisis que se realizaron en los distintos periodos de tiempo a las muestras sometidas a estabilidad fueron pruebas fisicoquímicas como: descripción, peso promedio, dureza, humedad, desintegración, disolución, dosaje y uniformidad. Finalmente por medio del estudio comparativo de los datos obtenidos del estudio de estabilidad con el producto de referencia se determinó que la formulación seleccionada para Gemfibrozilo 600 mg tableta recubierta cumple con todos los parámetros de calidad establecidos por las farmacopeas oficiales de referencia a temperaturas de almacenamiento de 25 ºC e inclusive a 32 ºC. Palabras claves: Gemfibrozilo tableta recubierta, compresión directa, granulación húmeda, estabilidad acelerada, estabilidad natural, estabilidad intermedia, factores de deferencia (F1) y similitud (F2)
Three Gemfibrozil 600 mg coated tablet formulations were evaluated, one manufactured by direct compression and two by wet granulation, it has been selected the one that fulfill the established parameters for dosage, dissolution, and the difference (F1) and similitude (F2) factors, these two factors are determined by comparison of the dissolution profile respect of the innovator product. It was developed the accelerated (40 °C ± 2 °C / 75% ± 5% relative humidity), long term (25 °C ± 2 °C / 60% ± 5% relative humidity) and intermediate (32 °C ± 2 °C / 65% ± 5% relative humidity) stability studies in two types of primary container (Aluminum blister and 250 um and 300 um PVC) and for the innovator product, the analysis was at the beginning of the stability study (zero time), in the third and sixth month and in the case of the environmental condition stability even the twelfth month. The methodology used for the physico-chemical and microbiological analysis was based on the United States Pharmacopoeia (USP 26 – NF 21) and the British Pharmacopoeia (BP 2003), the microbiology analysis was based European Pharmacopoeia 4ta Ed. 2002, the analysis that were performed to the stability-submit samples in the different periods of time were physicochemical tests: description, average weight, hardness, humidity, disintegration, dissolution, dosage and uniformity. Finally, through the comparative study of the stability data obtained with the innovator product it was determinate that the selected formulation for Gemfibrozilo 600 mg coated tablet complies all the quality parameters established by official reference pharmacopoeias at storage temperature of 25°C and even at 32 °C. Key words: Gemfibrozil 600 mg coated tablet, direct compression, wet granulation, accelerated stability, long term stability, intermediate stability, the difference (F1) and similitude (F2) factors.
Tesis
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Maguiña, Cacha Elbis Jhon, e Verástegui Diocelino Fernando Nuevo. "Análisis costo-efectividad del uso de estatinas frente a gemfibrozilo en pacientes de consultorios externos del Centro Médico Naval : Cirujano Mayor Santiago Távara". Bachelor's thesis, Universidad Nacional Mayor de San Marcos, 2006. https://hdl.handle.net/20.500.12672/2326.

Testo completo
Abstract (sommario):
El presente es un estudio transversal, descriptivo y retrospectivo realizado en el Centro Médico Naval “Santiago Távara”, ubicado en Av. Venezuela s/n Bellavista-Callao, con el objetivo de determinar y comparar el costo-efectividad de Estatinas (Atorvastatina 20mg y Pravastatina 20 mg) frente a Gemfibrozilo 600 mg en el tratamiento de hiperlipidemia durante el período de enero 2002 a julio 2005. Se revisaron las historias clínicas de 64 pacientes hiperlipidémicos, con edades entre los 40 y 64 años de ambos sexos que acuden a los consultorios externos de Cardiología, Endocrinología, Geriatría y Medicina Interna y a quienes se les prescribió algunos de los fármacos en estudio (54 Estatinas y 10 Gemfibrozilo). Además se aplicó una encuesta a los pacientes para conocer problemas de cumplimiento de terapia. El 60% de los pacientes con indicación de Gemfibrozilo, presentan Hipertrigliceridemia asociada con alteraciones del metabolismo de glucosa, y los factores de riesgo HDL-c bajo y sobrepeso u obesidad están presentes en un 90%. Según el análisis costo-efectividad (reducción del nivel sérico de LDL-c), las Estatinas resultaron con una relación costo-efectiva de 13,76 Nuevos soles por porcentaje de reducción; y el Gemfibrozilo, no resultó efectivo no pudiéndose establecer la relación costo- efectividad. Cuando la efectividad se mide por reducción de nivel de triglicéridos, el Gemfibrozilo presentó una relación costo-efectiva de 1,74 Nuevos soles por porcentaje de reducción y las Estatinas no fueron efectivas, no pudiéndose establecer la relación costo-efectividad. Cuando la efectividad se mide por logro de objetivos terapéuticos según el Tercer Panel para Adultos (ATP III) del National Cholesterol Education Program (NCEP 2001), el Gemfibrozilo presenta una relación costo-efectiva menor (361,2 Nuevos soles por paciente), debido a su menor costo.
-- This is a transversal, retrospective, descriptive study, carried out in the Centro Médico Naval “Santiago Távara” located at Avenida Venezuela s/n, Bellavista Callao, with the purpose of determining and comparing cost-effectiveness of Statins (Atorvastatin 20 mg and Pravastatin 20 mg) against Gemfibrozil 600 mg in hyperlipidemia treatment over a period from January 2002 to July 2005. 64 patient’s clinical record revision, who suffered with dyslipidemia of both genders, who were aged from 40 to 64 years old, attending in external medical service of Cardiology, Endocrinology, Geriatrics and Internal Medicine, was carried out. In order to know patient’s problem of therapy compliance , several inquiries were carried out. In patients with Gemfibrozil prescription, 60% have hypertriglyceridemia associated with alteration of glucose metabolism. Low HDL-c and Obesity or overweight factors risk were found in 90% patients at this group. According to cost-effectiveness analyses (for LDL-c level serumal reduction.), Statins showed a cost-effectiveness ratio of 13,76 Nuevos soles for reduction percentage and Gemfibrozil were not effective , it was not able to establish its cost – effectiveness ratio. When effectiveness is measured for level reduction of triglycerides, the Gemfibrozil showed a cost–effectiveness ratio of 1,74 Nuevos soles for reduction percentage and Statins were not effective , it was not able to establish its cost – effectiveness ratio. When effectiveness is measured for therapeutic objective achievement according to Adults Third Panel ( ATP III ) of the National Cholesterol Education Program ( NCEP 2001 ), Gemfibrozil shows a minor cost – effectiveness ratio ( 361,2 Nuevos soles for patient ), due to its low cost.
Tesis
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Hemingway, Cheryl Joy. "Investigation of the molecular mechanisms of inhibition of hepatic fatty acid and cholestral biosynthesis by hypolipidaemic agents". Thesis, University College London (University of London), 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.285489.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Chamouret, Sandrine. "Le gemfibrozil : étiologie possible de pneumopathies médicamenteuses : à propos de deux cas". Saint-Etienne, 1995. http://www.theses.fr/1995STET6222.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Prindiville, John S. "Circulating lipoproteins and tissue lipids: Effects of gemfibrozil on lipid metabolism in rainbow trout". Thesis, University of Ottawa (Canada), 2010. http://hdl.handle.net/10393/28555.

Testo completo
Abstract (sommario):
Lipids support crucial functions in teleost fish, including the production of energy; lipoproteins support the movement of lipids through the vascular system. The objective of this thesis was to determine if gemfibrozil (GEM), a mammalian PPARalpha agonist pharmaceutical, could alter the circulating lipoproteins and tissue lipid metabolism in the rainbow trout, Oncorhynchus mykiss. Injections of GEM lowered the concentration of lipoproteins and changed their size distribution, lipid and fatty acid content. These changes were associated with an increased lipoprotein lipase transcript level but not activity. GEM increased liver size but did not affect its lipid content nor the activities or transcript levels of its PPARs and mitochondrial/peroxisomal enzymes. This thesis provides evidence that the pharmacological effects of GEM are conserved across vertebrates. Furthermore, the decreased plasma lipids and altered lipoprotein composition demonstrated here may be relevant sublethal indicators of exposure to PPARalpha agonists present in the aquatic environment.
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Santos, Tiago André Azevedo dos. "Fish personality, memory and learning hability: the effect of pharmaceuticals and abiotic factors". Master's thesis, Universidade de Aveiro, 2017. http://hdl.handle.net/10773/22023.

Testo completo
Abstract (sommario):
Mestrado em Biologia Molecular e Celular
Over the last years, animal personality has been gaining a lot of attention from the scientific community, and, at the moment, it is being questioned its importance in survival and the evolution of species in stress situation. Between all of potential stress agents, there are emerging environmental contaminants, such as, pharmaceuticals. However, there are not many behavior and personality studies in fish. The present work aims to increase the knowledge of how factors associated with personality can influence the response to pharmaceuticals detected in the environment. For model organism, the zebrafish (Danio rerio) was chosen, and 8 months old organism were selected. Animals were separated, based on behavior responses, in two classes, bold and shy. After the selection, organisms were exposed, during 96h to a human drug, gemfibrozil, used as a lipid regulator. During the experimental assay, behavior parameters that allowed to evaluate the capacity of response to stimuli, and memory to adaptation were assessed. After 96h of exposure, associated parameters and oxidative stress were equally assessed. Bold fish traveled a bigger distance than shy fish. Furthermore, shy fish expressed higher LPO levels than bold fish, and fish from the control group, as well as, shy fish exposed to the lowest concentration of gemfibrozil expressed more LPO than shy fish exposed to the higher concentrations of gemfibrozil
Nos últimos anos, a personalidade animal tem vindo a atrair a atenção da comunidade científica, estando neste momento a ser questionada a hipótese de da sua importância na sobrevivência e a evolução das espécies em situação de stress. De entre os diferentes potenciais agentes causadores de stress estão os contaminantes ambientais emergentes como, por exemplo, os fármacos. No entanto não existem muitos estudos de comportamento e personalidade dos peixes. Este trabalho visou aumentar o conhecimento de como fatores associados a personalidade podem influenciar a resposta a fármacos detetados no ambiente. Como organismo modelo foi escolhido o peixe zebra (Danio rerio), tendo sido selecionado organismos com 8 meses. Os animais foram separados, com base em resposta comportamentais, em duas classes, proativos e reativos. Após a separação, os organismos foram expostos, durante 96h a um fármaco humano, gemfibrozil, utilizado como regulador lipídico. Ao longo do ensaio experimental foram avaliados parâmetros comportamentais que permitiram avaliar a capacidade de resposta a estímulo, memória a adaptação. Ao fim de 96 h de exposição, parâmetros associados e stress oxidativo foram igualmente avaliados. Os peixes proativos percorreram uma maior distância que os peixes retroativos. Para além disso, os peixes retroativos expressaram níveis maiores de LPO que os peixes proativos, e os peixes retroativos do controlo e expostos à menor concentração de gemfibrozil expressaram mais LPO que os peixes retroativos expostos às concentrações maiores de gemfibrozil.
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Filho, José Joaquim Fernandes Raposo. "Suco de laranja tem efeito sinérgico à estatina e ao genfibrozila no tratamento da aterosclerose". Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5131/tde-22092010-162733/.

Testo completo
Abstract (sommario):
FUNDAMENTO: O suco de laranja (Citrus sinensis) é rico em vitami-na C, folatos e seu principal flavonóide, a hesperidina, cuja conformação es-pacial é semelhante à genisteína de soja que tem ação favorável sobre o aparelho cardiovascular. A vitamina C é conhecida como potente inibidor da peroxidação lipídica. Mas sua capacidade por possuir efeitos terapêuticos no tratamento da aterosclerose é pouco estudada. OBJETIVO: O presente tra-balho visa a determinar se o suco de laranja pode ter efeito aditivo no trata-mento com estatinas e fibratos, reduzindo placas ateroscleróticas e a quanti-dade de LDL Oxidado (LDL ox). MÉTODOS: Análise do efeito do suco nas dimensões de cortes histológicos e na quantidade de anticorpos anti LDL oxidado (antiLDLox) em lesões ateroscleróticas na aorta de coelhos. RE-SULTADOS: O suco de laranja potencializou a redução de área de placas ateroscleróticas e a quantidade de LDL(ox) em relação às reduções obtidas com rosuvastatina e gemfibrozil. CONCLUSÕES: O suco de laranja tem efei-to sinérgico ao tratamento convencional da aterosclerose de coelhos
Statins and fibrates have been used as anti-atherosclerotic drugs. However, a high number of treated patients still present acute events and death by atherosclerotic complications. Flavonoid ingestion has been associ-ated with lower risk of death, lower incidence of coronary artery disease and more preserved endothelial function in atherosclerotic patients. Orange juice is rich in C vitamine, a well known potent inhibitor of lipidic peroxidation, and in flavonoids, mainly the hesperidine that seems the soy bean genisteine, which is associated with decrease LDL and increase HDL. Objective: In this work we studied if orange juice has addictive effect to statin and gemfibrozil in the treatment of rabbit atherosclerosis, reducing plaque area and oxidate LDL (LDLox). Methods: Five group of atherosclerotic rabbits, fed with 1% cholesterol enriched diet during 12 weeks, were analyzed: GI - received no treatment, GII Gemfibrozil 600mg/day, GIII treated with Gemfibrozil 600mg/day + orange juice, GIV - rosuvastatin/10mg / day and GV - rosu-vastatin/10mg / day + orange juice. The most severe atherosclerotic cross section in ascendant aorta was analyzed in H&E and anti-oxidated LDL (oxLDL) immunostained slides, obtaining intimal area, total vessel area, % luminal obstruction and % oxLDL area in intima. Results: The means (stan-dard deviations) of plaque area and % plaque area of oxLDL in GI were 1.05 (0.91) and 0.12 (0.13), with no significant difference with GII animals, respec- tively 3.85 (5.27) and 0.18 (0.22), but significantly reduced in GIII, 0.64 (1.56) and 0.03 (0.05). Similar data were seen in GIV, 2.11 (2.77) and 0.19 (0.25), compared with GV, 0.04 (0.09) and 0.00 (0.00). Conclusion: This work de-monstrates that orange juice has a potential synergistic action with statin and fibrates in reducing atherosclerosis and the mechanism seems to involve in-hibition of oxLDL concentration and migration of smooth muscle cells in the subendothelial space
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Laser, Eric [Verfasser], Olaf [Gutachter] Picker e Georg [Gutachter] Flügen. "Der Einfluss von Gemfibrozil und Pravastatin auf die mitochondriale Funktion im Colon und in der Leber in vitro - Ein Therapieansatz bei Sepsis? / Eric Laser ; Gutachter: Olaf Picker, Georg Flügen". Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2021. http://d-nb.info/1230135111/34.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Bergman, Ebba. "The Hepatobiliary Transport of Rosuvastatin In Vivo". Doctoral thesis, Uppsala universitet, Institutionen för farmaci, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-109866.

Testo completo
Abstract (sommario):
In vivo studies of hepatobiliary disposition are challenging. The hepatobiliary system is complex, as its physiological localization, complex cellular structure with numerous transporters and enzymes, and the interindividual variability in protein expression and biliary flow will all affect the in vivo disposition of a drug under investigation. The research included in this thesis has focused on the involvement of hepatic transport proteins in the hepatobiliary disposition of rosuvastatin. The impact that several transport inhibitors had on the pharmacokinetics of rosuvastatin was investigated in healthy volunteers and in pigs. The effects were considerable, following inhibition of sinusoidal transport proteins by cyclosporine and rifampicin. These inhibitors significantly reduced the hepatic extraction of rosuvastatin by 50 and 35%, respectively, and the plasma exposure increased by factors of 9.1 and 6.3, respectively. Drug-drug interactions (DDI) resulting in markedly higher plasma exposures are important from a drug safety perspective as increased extrahepatic exposure of statins is associated with an increased risk of severe side-effects, such as myopathy which in rare cases could develop into rhabdomyolysis. The DDI caused by cyclosporine and rifampicin can probably be attributed to inhibition of hepatic uptake transporters. In contrast, inhibition of canalicular transporters by imatinib did not significantly affect the pharmacokinetics of rosuvastatin, which suggests that the intracellular concentration of the inhibitor in the hepatocyte was insufficient to affect the transport of rosuvastatin, or that imatinib is not a sufficiently potent inhibitor in vivo. Furthermore, gemfibrozil administered as a single dose into the jejunum in healthy volunteers and pigs did not affect the plasma or biliary pharmacokinetics of rosuvastatin. The previously reported DDI in humans upon repeated dosing with gemfibrozil might be explained by the accumulation of metabolites able to affect the disposition of rosuvastatin. The investigations presented in this thesis conclude that transport proteins are of considerable importance for the hepatobiliary disposition of rosuvastatin in vivo. The Loc-I-Gut catheter can be applied for the investigation of biliary accumulation and to determine bile specific metabolites, however it has limitations when conducting quantitative measurements. In the porcine model, hepatic bile can be collected for up to six hours and enables the determination of the hepatic extraction in vivo.
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Dah-Chung, Owe Yang, e 歐陽大中. "The Synthesis of Gemfibrozil". Thesis, 1994. http://ndltd.ncl.edu.tw/handle/75834394951751380638.

Testo completo
Abstract (sommario):
碩士
國立成功大學
化學工程研究所
82
2,2-dimethyl-5(2,5-xylyloxy) valeric acid, known as gemfibrozil, and used for treatment or prevention of arteriosclerosis, can be produced by these ways: (1) Abstraction of proton from Me2CHCOPh using NaNH2 followed by alkylation with Br(CH2)3Cl resulted in Cl(CH2)3CMe2COPh(b). Refluxing b with anhydrous K2CO3,KI and 2,5-xylenol in a medium polar solvent gave 2,5-Me2C6H3O(CH2)3CMe2COPh. The latter was heated with KOCMe3 in anisole to yield gemfibrozil. The results from GC-MASS, NMR, EA and IR comfirmed the presence of product. The overall yield was 15.97%. Although the result was not good, however we have understood some key points about the synthesis. (2) Abstraction of proton from HCMe2COOR (R is H or alkyl) followed by alkylation with an alkyl halide, 2,5-Me2C6H3O(CH2)3 Cl, also gave Gemfibrozil。 We only suceededonce by this way.
Gli stili APA, Harvard, Vancouver, ISO e altri
Più fonti

Libri sul tema "Gemfibrozilo"

1

Sarma, Syam. The gemfibrozil cost-benefit model: Analysis of data from the Helsinki Heart Study, model development, and extension to the California Medicaid population. Santa Monica, CA (1700 Main St., P.O. Box 2138, Santa Monica 90407-2138): RAND, 1993.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Sarma, Syam. The gemfibrozil cost-benefit model: Analysis of data from the Helsinki Heart Study, model development, and extension to the California Medicaid population. Santa Monica, CA (1700 Main St., P.O. Box 2138, Santa Monica 90407-2138): RAND, 1993.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Sarma, Syam. The gemfibrozil cost-benefit model: Analysis of data from the Helsinki Heart Study, model development, and extension to the California Medicaid population. Santa Monica, CA (1700 Main St., P.O. Box 2138, Santa Monica 90407-2138): RAND, 1993.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Sarma, Syam. The gemfibrozil cost-benefit model: Analysis of data from the Helsinki Heart Study, model development, and extension to the California Medicaid population. Santa Monica, CA: RAND, 1993.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Sarma, Syam. The gemfibrozil cost-benefit model: Analysis of data from the Helsinki Heart Study, model development, and extension to the California Medicaid population. Santa Monica, CA (1700 Main St., P.O. Box 2138, Santa Monica 90407-2138): RAND, 1993.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Wood, Clive. Further Progress With Gemfibrozil. Royal Society of Medicine, 1987.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Publications, ICON Health. Gemfibrozil - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri

Capitoli di libri sul tema "Gemfibrozilo"

1

Ciuffetti, G., G. Orecchini, D. Siepi, G. Lupattelli e A. Ventura. "Hemorheological Activity of Gemfibrozil in Primary Hyperlipidemias". In Drugs Affecting Lipid Metabolism, 372–75. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71702-4_69.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Giudici, G. A., F. Pagani, C. Selvini, P. Stefanoni, C. Di Santo e C. Vergani. "Effects of Gemfibrozil on Lipoproteins in Patients with Dyslipoproteinemia". In Drugs Affecting Lipid Metabolism, 358–66. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71702-4_67.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Steiner, G. "Relationship of glucose intolerance and elevated triglyceride: implications for gemfibrozil". In Atherosclerosis and Cardiovascular Diseases, 225–29. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3205-0_28.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Yoshida, Hiroshi, Makoto Ayaori, Tetsuya Hisada, Toshitsugu Ishikawa, Fumitaka Ohsuzu e Haruo Nakamura. "Beneficial Effect of Gemfibrozil on LDL Chemicophysical Characteristics and Oxidizability". In Lipoprotein Metabolism and Atherogenesis, 74–76. Tokyo: Springer Japan, 2000. http://dx.doi.org/10.1007/978-4-431-68424-4_17.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Manzato, E., S. Zambon, R. Marin, G. Baggio e G. Crepaldi. "Plasma Lipids, Lipoproteins, and Apoproteins During Gemfibrozil Treatment in Primary Hyperlipidemias". In Drugs Affecting Lipid Metabolism, 355–57. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71702-4_66.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Kashyap, M. L., e K. Saku. "HDL Deficiency, Atherosclerosis, and Stimulation of HDL Synthesis: Role of Gemfibrozil". In Drugs Affecting Lipid Metabolism, 367–71. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71702-4_68.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Barbara, L., G. Mazzella, N. Villanova, P. Simoni, M. Ronchi, A. Roda, E. Roda e F. Bazzoli. "Effect of Gemfibrozil Administration on Biliary Lipid Secretion: A Crossover Study with Clofibrate". In Drugs Affecting Lipid Metabolism, 350–54. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71702-4_65.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Allhoff, Peter, Ulrich Laaser e Joachim Heinrich. "Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle Aged Men with Dyslipidemia". In Kompendium der Lipid-Studien, 66–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-95642-3_30.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Kashyap, Moti L., e Keijiro Saku. "HDL Metabolism in HDL Deficiency Associated with Familial Hypertriglyeridemia: Effect of Treatment with Gemfibrozil". In Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, in Vivo Kinetics, 233–36. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4684-5904-3_28.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
10

van Tol, Arie, Juhani Kahri, Bernhard Eisele, Timo Sane e Marja-Riitta Taskinen. "Gemfibrozil Increases Plasma Levels of Cholesterylester Transfer Protein (Cetp), But Lowers Cholesterylester Transfer in Hypertriglyceridemic Subjects". In Drugs Affecting Lipid Metabolism, 557–65. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0311-1_65.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri

Atti di convegni sul tema "Gemfibrozilo"

1

Benitta, T. Asenath, G. K. Balendiran, C. James, V. K. Vaidyan e V. S. Jayakumar. "Vibrational Spectral Studies of Gemfibrozil". In PERSPECTIVES IN VIBRATIONAL SPECTROSCOPY: Proceedings of the 2nd International Conference on Perspectives in Vibrational Spectroscopy (ICOPVS 2008). AIP, 2008. http://dx.doi.org/10.1063/1.3046218.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Laustiola, K., R. Lassila, P. Koskinen e V. Manninen. "GEMFIBROZIL HAS ANTI-PLATELET EFFECTS IN PATIENTS WITH HYPERCHOLESTEROLAEMIA DURING PHYSICAL STRESS". In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643462.

Testo completo
Abstract (sommario):
Earlier studies indicate an increased platelet reactivity in patients with hypercholesterolaemia. Physical and mental stress have also been reported to cause increased reactivity. The present study was undertaken to evaluate the effect of gemfibrozil (G) a new lipid lowering drug on platelet reactivity during physical stress. Ten otherwise healthy male subjects with serum cholesterol levels above 7 mmol/l were involved in a double-blind study. It consisted of two treatment periods of 8 weeks during which the patients were given either G (600 mg b.i.d.) or placebo (PI) and an 8 weeks wash-out period before the cross-over. At the end of the treatment periods an exercise test was carried out and platelet reactivity tested. Adrenaline, ADP and collagen were used to induce aggregation and 5-HT and T×B2 release measured. Plasma beta-TG and fibrinogen were also determined.The treshold concentration of adrenaline necessary to evoke secondary aggregation was increased in 8/10 patients during exercise after G treatment and in 2/10 after PI. When the lowest ADP concentration to cause secondary aggregation (2-4 uM) was used there was a significant decrease in the 5-HT (− 44%) and T×B2 (− 48%) secretion and a significant decrease in the area under the aggregation curve (− 28%). A decrease in 5-HT secretion was also seen after G treatment when a fixed ADP concentration of 10 uM was used. During collagen stimulation no changes were seen between the two groups. Beta-TG remained unchanged irrespective of treatment and fibrinogen showed a modest increase during exercise in both treatment groups. These results indicate a new anti-platelet effect of gemfibrozil which might be of importance in prevention of acute thrombotic events in hypercho1estero1aemic patients.
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Liu, Yanghe, Chenguang Sheng e George Agbai Nnanna. "Detection of Selected Pharmaceutical Contaminants and Removal Efficiency of Emerging Contaminants by Application of Membrane Filtration Technology". In ASME 2014 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/imece2014-36906.

Testo completo
Abstract (sommario):
Removal of emerging contaminants is considered to be one of the most important processes within advanced Waste Water Treatment Plants (WWTPs) system. Pharmaceutical contaminants in drinking water could potentially lead to human’s increasing risks of heart attacks, organ damage, mental health and even cancer. This paper investigates the emerging contaminant removal efficiencies of technologies employed by local WWTPs. After determining the presence of selected emerging contaminants (17β-estradiol, Acetaminophen, Carbamazepine, Diclofenac, Erythromycin, Estrone, Bezafibrate, Fluoxetine, Gemfibrozil, Ibuprofen, Lincomycin, Metoprolol, Naproxen, Ofloxacin, Sulfamethoxazole and Triclosan) in the waterbodies within the watershed of Lake Michigan in Northwest Indiana (NWI). Three of the contaminants above are chosen for lab experiments by considering their effects on human’s health and environment. A membrane filtration experiment is conducted in Purdue Water Institute (PWI) as preliminary studies on the removal of selected emerging contaminants. Meanwhile, application of Powdered Activated Carbon (PAC) and simulation of coagulation/flocculation are designed as combined experiment with membrane filtration for evaluation of feasibility of using these techniques.
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Sheng, Chenguang, A. G. Agwu Nnanna, Yanghe Liu e John D. Vargo. "Removal of Pharmaceutical Contaminants in Water". In ASME 2015 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2015. http://dx.doi.org/10.1115/imece2015-53240.

Testo completo
Abstract (sommario):
Pharmaceutical contaminants in drinking water could potentially lead to increasing risks of heart attacks, organ damage, mental health and even cancer. Because their presence, frequency of occurrence, or source may not be known, the chemicals being discovered in water that previously had not been detected or are being detected at levels that may be significantly different than expected. Removal of emerging contaminants is considered recently to be one of the most important processes within advanced Waste Water Treatment Plants (WWTPs) system. EPA is working to improve its understanding of a number of emerging contaminants, particularly pharmaceuticals and personal care products (PPCPs). The objectives of this research are: 1) to identify the presence of selected emerging contaminants (Acetaminophen, Bezafibrate, Caffeine, Carbamazepine, Cotinine, Diclofenac, Gemfibrozil, Ibuprofen, Metoprolol, Naproxen, Sulfadimethoxine, Sulfamethazine, Sulfamethoxazole, Sulfathiazole, Triclosan and Trimethoprim). These contaminants were selected based on analyte selection criteria such as occurrence and availability of analytical standards, chronological ecotoxicity and environment relevance concentration, volume of use, and priority ranking, as well as literature survey on environmental occurrence studies in local WWTPs; 2) to estimate the corresponding WWTPs’ removal efficiency; and the third objective is to evaluate the feasibility of applying ultra-filtration (UF) membrane combined with pretreatments — powder activated carbon (PAC), coagulation, and sand filtration to remove the above emerging contaminants. This paper appraises the efficacy of ultra-filtration membrane coupled pretreatments to mitigate the presence of pharmaceutical contaminants in water. This work is a sequel to an earlier work, Liu et al., published in 2014 ASME-IMECE conference proceedings. In this study, water samples were analyzed using direct aqueous injection High Performance Liquid Chromatography with Tandem Quadrupole Mass Spectrometric (LC/MS/MS) detection. Through the project research period, both historical concentrations from WWTPs and experimental removal efficiency data were obtained. Results showed that conventional WWTP failed to remove Carbamazepine, Diclofenac and Trimethoprim, and in some cases, the concentration of these contaminants at the effluent were higher than influent concentration. Secondly, the ultrafiltration membrane system by itself was insufficient to remove the selected contaminants. However, the use of PAC as a pretreatment to the UF system was effective in removing most of the contaminants, and the removal efficiency was a function of PAC dosage. Results indicated that there is an optimum dosage where the removal efficiency must be balanced with the cost of PAC. Unlike PAC, coagulation coupled with filtration process, was not able to increase the contaminants removal efficiency significantly. Additionally, the historical data indicated there was no dramatic fluctuation of the target contaminants level during the 12-month monitoring period.
Gli stili APA, Harvard, Vancouver, ISO e altri
Ti possono interessare anche gli elenchi estesi di opere sul tema "Gemfibrozilo":
Articoli di riviste Tesi
Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!

Vai alla bibliografia